Design And Evaluation Of Meloxicam Tablet For Colon Cancer

Abstract

Meloxicam, recognized as a preferential COX-2 inhibitor, has emerged as a promising chemopreventive agent for colorectal cancer. Leveraging its local and targeted action on the colon, Meloxicam proves to be a formidable component in the prevention of colorectal malignancies. This study aims to innovate by formulating and evaluating a targeted tablet delivery system for Meloxicam, emphasizing site-specific and instant drug release in the colon, thereby maximizing its therapeutic efficacy in the treatment of colorectal cancer. Acknowledging Meloxicam's challenges as an extremely poorly soluble acidic drug with pH-dependent solubility, the formulation incorporates buffering agents to ensure pH-independent drug release upon reaching the colon. In vitro evaluations of the coated tablets, containing 2% croscarmelose and 4% crospovidone as disintegrants, demonstrate immediate drug release within the colon. Notably, the tablet's drug content, standing at 96.9%, aligns with the standards outlined by the United States Pharmacopeia (USP). This substantiates the formulation's compliance with regulatory benchmarks, indicating its potential for clinical application. In conclusion, this study affirms the efficacy of the Meloxicam targeted tablet formulation, showcasing its potential as an advanced and targeted drug delivery system for the treatment of colorectal cancer.